The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population

Soha Dargham, Lina Ahmed, Eric S. Kilpatrick, Stephen Atkin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVE: The prevalence of polycystic ovary syndrome (PCOS) in the Qatari population is unknown and hence the estimated impact on the local population cannot be determined. The purpose of this study was to estimate the prevalence and metabolic features of PCOS among Qatari women.

DESIGN: Cross sectional analysis.

PATIENTS: 3,017 Qatari subjects volunteered to be phenotyped and genotyped for the Qatar Biobank from which all women between the ages of 18-40 years were identified (750).

MEASUREMENTS: 720 women had testosterone and sex hormone binding globulin (SHBG) measurements. PCOS was diagnosed according the National Institute of Health (NIH) Guidelines of a raised androgen level (free androgen index >4.5 or a raised total testosterone) and menstrual irregularity after the exclusion of other conditions.

RESULTS: All results are reported as mean value of PCOS versus control. 87 of 720 women fulfilled the NIH guidelines (12.1%) for PCOS specifically using a free androgen index greater than 4.5 or a total testosterone greater than 2.7nmol/l and menstrual irregularity. Subjects were heavier with a more metabolic profile of a greater systolic and diastolic blood pressure, higher levels of C reactive protein, insulin (p<0.01) and HbA1c (P<0.02), and decreased HDL levels (p<0.01). Pulse wave velocity as a marker of arterial stiffness was also increased (p<0.05).

CONCLUSIONS: By NIH guidelines the prevalence of PCOS in this Qatari cohort was 12.1% that would likely reflect 20% by Rotterdam criteria, with a markedly more metabolic phenotype than Qatari controls.

Original languageEnglish
Pages (from-to)e0181467
JournalPLoS One
Volume12
Issue number7
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint

polycystic ovary syndrome
Polycystic Ovary Syndrome
Androgens
Testosterone
Health
National Institutes of Health
National Institutes of Health (U.S.)
androgens
Population
testosterone
Sex Hormone-Binding Globulin
Blood pressure
Guidelines
C-Reactive Protein
Qatar
Stiffness
Insulin
Blood Pressure
Pulse Wave Analysis
glycohemoglobin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population. / Dargham, Soha; Ahmed, Lina; Kilpatrick, Eric S.; Atkin, Stephen.

In: PLoS One, Vol. 12, No. 7, 01.01.2017, p. e0181467.

Research output: Contribution to journalArticle

@article{9f1b5d7f4ddc41db80f2b7f226f60d10,
title = "The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population",
abstract = "OBJECTIVE: The prevalence of polycystic ovary syndrome (PCOS) in the Qatari population is unknown and hence the estimated impact on the local population cannot be determined. The purpose of this study was to estimate the prevalence and metabolic features of PCOS among Qatari women.DESIGN: Cross sectional analysis.PATIENTS: 3,017 Qatari subjects volunteered to be phenotyped and genotyped for the Qatar Biobank from which all women between the ages of 18-40 years were identified (750).MEASUREMENTS: 720 women had testosterone and sex hormone binding globulin (SHBG) measurements. PCOS was diagnosed according the National Institute of Health (NIH) Guidelines of a raised androgen level (free androgen index >4.5 or a raised total testosterone) and menstrual irregularity after the exclusion of other conditions.RESULTS: All results are reported as mean value of PCOS versus control. 87 of 720 women fulfilled the NIH guidelines (12.1{\%}) for PCOS specifically using a free androgen index greater than 4.5 or a total testosterone greater than 2.7nmol/l and menstrual irregularity. Subjects were heavier with a more metabolic profile of a greater systolic and diastolic blood pressure, higher levels of C reactive protein, insulin (p<0.01) and HbA1c (P<0.02), and decreased HDL levels (p<0.01). Pulse wave velocity as a marker of arterial stiffness was also increased (p<0.05).CONCLUSIONS: By NIH guidelines the prevalence of PCOS in this Qatari cohort was 12.1{\%} that would likely reflect 20{\%} by Rotterdam criteria, with a markedly more metabolic phenotype than Qatari controls.",
author = "Soha Dargham and Lina Ahmed and Kilpatrick, {Eric S.} and Stephen Atkin",
year = "2017",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0181467",
language = "English",
volume = "12",
pages = "e0181467",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population

AU - Dargham, Soha

AU - Ahmed, Lina

AU - Kilpatrick, Eric S.

AU - Atkin, Stephen

PY - 2017/1/1

Y1 - 2017/1/1

N2 - OBJECTIVE: The prevalence of polycystic ovary syndrome (PCOS) in the Qatari population is unknown and hence the estimated impact on the local population cannot be determined. The purpose of this study was to estimate the prevalence and metabolic features of PCOS among Qatari women.DESIGN: Cross sectional analysis.PATIENTS: 3,017 Qatari subjects volunteered to be phenotyped and genotyped for the Qatar Biobank from which all women between the ages of 18-40 years were identified (750).MEASUREMENTS: 720 women had testosterone and sex hormone binding globulin (SHBG) measurements. PCOS was diagnosed according the National Institute of Health (NIH) Guidelines of a raised androgen level (free androgen index >4.5 or a raised total testosterone) and menstrual irregularity after the exclusion of other conditions.RESULTS: All results are reported as mean value of PCOS versus control. 87 of 720 women fulfilled the NIH guidelines (12.1%) for PCOS specifically using a free androgen index greater than 4.5 or a total testosterone greater than 2.7nmol/l and menstrual irregularity. Subjects were heavier with a more metabolic profile of a greater systolic and diastolic blood pressure, higher levels of C reactive protein, insulin (p<0.01) and HbA1c (P<0.02), and decreased HDL levels (p<0.01). Pulse wave velocity as a marker of arterial stiffness was also increased (p<0.05).CONCLUSIONS: By NIH guidelines the prevalence of PCOS in this Qatari cohort was 12.1% that would likely reflect 20% by Rotterdam criteria, with a markedly more metabolic phenotype than Qatari controls.

AB - OBJECTIVE: The prevalence of polycystic ovary syndrome (PCOS) in the Qatari population is unknown and hence the estimated impact on the local population cannot be determined. The purpose of this study was to estimate the prevalence and metabolic features of PCOS among Qatari women.DESIGN: Cross sectional analysis.PATIENTS: 3,017 Qatari subjects volunteered to be phenotyped and genotyped for the Qatar Biobank from which all women between the ages of 18-40 years were identified (750).MEASUREMENTS: 720 women had testosterone and sex hormone binding globulin (SHBG) measurements. PCOS was diagnosed according the National Institute of Health (NIH) Guidelines of a raised androgen level (free androgen index >4.5 or a raised total testosterone) and menstrual irregularity after the exclusion of other conditions.RESULTS: All results are reported as mean value of PCOS versus control. 87 of 720 women fulfilled the NIH guidelines (12.1%) for PCOS specifically using a free androgen index greater than 4.5 or a total testosterone greater than 2.7nmol/l and menstrual irregularity. Subjects were heavier with a more metabolic profile of a greater systolic and diastolic blood pressure, higher levels of C reactive protein, insulin (p<0.01) and HbA1c (P<0.02), and decreased HDL levels (p<0.01). Pulse wave velocity as a marker of arterial stiffness was also increased (p<0.05).CONCLUSIONS: By NIH guidelines the prevalence of PCOS in this Qatari cohort was 12.1% that would likely reflect 20% by Rotterdam criteria, with a markedly more metabolic phenotype than Qatari controls.

UR - http://www.scopus.com/inward/record.url?scp=85030446352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030446352&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0181467

DO - 10.1371/journal.pone.0181467

M3 - Article

VL - 12

SP - e0181467

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

ER -